Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market.
The company will acquire entire shareholding of QliniQ B.V. for a total consideration of 7.50 million euro. The acquisition is expected to be completed by June 15, 2026 or any other date as the Parties agree in writing.
This acquisition will enable the company to use the front-end sales and marketing infrastructure of QliniQ B.V. for marketing its products manufactured in India, UK, and USA regions. It will bolster the company’s presence in the European markets.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
